Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 75 |
| Active Pipeline (Recruiting Now) | 54 (37) |
| Completed vs Stopped Early | 3 / 6 (8.0%) |
| Median Closed Actual Enrollment | 121 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 8 |
| Zhongshan Hospital Fudan University | Shanghai | 7 |
| Beijing Cancer Hospital | Beijing, Beijing Municipality | 7 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05149807 | Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer | Phase II/III | TERMINATED |
Explore interactive annual charts and M&A subsidiary rollups in the Suzhou Suncadia Biopharmaceuticals Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.